POINT trial

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT)


The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke.

Patients who have had a TIA have a higher risk of having a major stroke. Recognizing and treating TIAs can reduce the risk of a stroke. Often, medication to prevent blood clots from forming is used to prevent a stroke in patients with blockage of one of the arteries in the brain. Low-dose aspirin has been shown to be effective in preventing strokes and heart attacks in patients who have had a TIA. Clopidogrel is another medication that is used to prevent strokes and heart attacks in patients at risk for these problems.

Principal Investigator(s)
Rodney Short, MD
National Institutes of Health StrokeNET
Genesis Research at 563-421-3941


  • Genesis Medical Center, West Central Park
    1401 West Central Park Avenue
    Davenport, IA 52804
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office